Rivaroxaban and Levaquin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Rivaroxaban (rivaroxaban) and Levaquin (levofloxacin). Common drug interactions include renal failure among females and sepsis among males.

The phase IV clinical study analyzes what interactions people have when they take Rivaroxaban and Levaquin. It is created by eHealthMe based on reports of 44 people who take the same drugs from the FDA, and is updated regularly.

What is Rivaroxaban?

Rivaroxaban has active ingredients of rivaroxaban. It is often used in blood clots. eHealthMe is studying from 26,544 Rivaroxaban users. Check the latest studies of Rivaroxaban.

What is Levaquin?

Levaquin has active ingredients of levofloxacin. It is often used in sinusitis. eHealthMe is studying from 56,638 Levaquin users. Check the latest studies of Levaquin.



On Aug, 02, 2026

44 people who take Rivaroxaban and Levaquin together, and have interactions are studied.

Rivaroxaban and Levaquin drug interactions.

What are the common drug interactions of Rivaroxaban and Levaquin, by gender? *:

female:

  1. Renal failure (kidney dysfunction)
  2. Chronic kidney disease
  3. Confusional state
  4. Hepatic failure (liver failure)
  5. Neoplasm progression (growth of tumour)
  6. Renal injury (kidney injury)
  7. Anaemia (lack of blood)
  8. Large intestine perforation (hole in large intestine)
  9. Pelvic abscess
  10. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)

male:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Cardiac failure
  3. Dyspnoea (difficult or laboured respiration)
  4. Ear pain
  5. Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
  6. Influenza like illness
  7. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
  8. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  9. Pain in jaw
  10. Sputum increased

What are the common drug interactions of Rivaroxaban and Levaquin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Abdominal discomfort
  2. Abdominal pain
  3. Dehydration (dryness resulting from the removal of water)
  4. Epistaxis (bleed from the nose)
  5. Haematuria (presence of blood in urine)
  6. Haemoglobin decreased
  7. Myasthenic syndrome (a group of conditions characterized by muscle weakness (myasthenia) that worsens with physical exertion)
  8. Pelvic venous thrombosis (blood clot occurring inside a blood vessel and thromboses (dvts) that form in the deep veins of the legs or in the pelvic veins)
  9. Pulmonary alveolar haemorrhage (acute bleeding)
  10. Pulmonary embolism (blockage of the main artery of the lung)

40-49:

  1. Renal failure (kidney dysfunction)
  2. Chronic kidney disease

50-59:

  1. Confusional state
  2. Hepatic failure (liver failure)
  3. Neoplasm progression (growth of tumour)
  4. Alanine aminotransferase increased
  5. Aspartate aminotransferase increased
  6. Pyrexia (fever)

60+:

  1. Arthralgia (joint pain)
  2. Chest discomfort
  3. Pyrexia (fever)
  4. Sputum increased
  5. Vitamin a deficiency
  6. Wheezing (a high-pitched whistling sound made while you breath)
  7. Sepsis (a severe blood infection that can lead to organ failure and death)
  8. Influenza like illness
  9. Cardiac failure
  10. Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)

What are the existing conditions these people have? *

  1. High Blood Pressure: 21 people, 47.73%
  2. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 16 people, 36.36%
  3. Pneumonia: 12 people, 27.27%
  4. Pain: 10 people, 22.73%
  5. Insomnia (sleeplessness): 9 people, 20.45%
  6. Constipation: 9 people, 20.45%
  7. Cough: 8 people, 18.18%
  8. Cystic Fibrosis (disease of the secretary glands): 8 people, 18.18%
  9. Dyspnea (difficult or laboured breathing): 8 people, 18.18%
  10. Stress And Anxiety: 8 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Rivaroxaban and Levaquin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Rivaroxaban and Levaquin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rivaroxaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Levaquin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rivaroxaban and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Levaquin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on rivaroxaban and levofloxacin (the active ingredients of Rivaroxaban and Levaquin, respectively), and Rivaroxaban and Levaquin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: